CSL Limited
CSL
Κατάταξη σε μετοχές
#360
CSL Limited operates as a global biopharmaceutical company, engaged in the... CSL Limited operates as a global biopharmaceutical company, engaged in the research, development, manufacturing, marketing, and distribution of diverse pharmaceutical and allied products. Its extensive international footprint includes key markets such as Australia, the United States, Germany, the United Kingdom, Switzerland, and China. The company is structured into two principal operating segments: CSL Behring and CSL Seqirus. CSL Behring focuses on plasma-derived therapies, encompassing both plasma products and recombinant treatments. This segment also conducts significant research into both plasma and non-plasma therapeutics and derives revenue from intellectual property licensing and royalties. In contrast, CSL Seqirus is dedicated to the manufacturing and worldwide distribution of non-plasma biotherapeutic products, alongside developing a range of influenza-related solutions. Founded in 1916, CSL Limited maintains its corporate headquarters in Parkville, Australia.
Τιμή μετοχής
$139.18
Κεφαλαιοποίηση
$66.79B
Αλλαγή (1 ημέρα)
1.16%
Αλλαγή (1 έτος)
-1.87%
Χώρα
AU
Εμπόριο CSL Limited (CSL)
Κατηγορία
Healthcare
Δείκτης P/B για CSL Limited (CSL)
Δείκτης P/B στις October 2026 TTM: 4.21
Σύμφωνα με τις τελευταίες οικονομικές αναφορές και την τιμή μετοχής της CSL Limited, ο τρέχων δείκτης P/B (TTM) είναι 4.21. Στο τέλος του 2024, η εταιρεία είχε P/B δείκτη 5.43.
Ιστορικό P/B για την CSL Limited από 2000 έως 2026
Δείκτης P/B στο τέλος κάθε έτους
| Έτος | Δείκτης P/B | Αλλαγή |
|---|---|---|
| 2026 (TTM) | 4.21 | 6.80% |
| 2025 | 3.94 | -27.38% |
| 2024 | 5.43 | 44.67% |
| 2023 | 3.75 | -8.59% |
| 2022 | 4.11 | -64.62% |
| 2021 | 11.60 | -41.84% |
| 2020 | 19.95 | 52.81% |
| 2019 | 13.06 | -17.71% |
| 2018 | 15.87 | -20.12% |
| 2017 | 19.87 | 32.34% |
| 2016 | 15.01 | -0.22% |
| 2015 | 15.04 | 47.75% |
| 2014 | 10.18 | 1.25% |
| 2013 | 10.06 | 70.32% |
| 2012 | 5.91 | 28.39% |
| 2011 | 4.60 | -10.55% |
| 2010 | 5.14 | 17.45% |
| 2009 | 4.38 | -40.16% |
| 2008 | 7.31 | -12.44% |
| 2007 | 8.35 | 25.21% |
| 2006 | 6.67 | 58.64% |
| 2005 | 4.21 | 53.56% |
| 2004 | 2.74 | 23.37% |
| 2003 | 2.22 | -67.73% |
| 2002 | 6.88 | -56.70% |
| 2001 | 15.89 | 71.69% |
| 2000 | 9.25 | 0.00% |
Δείκτης P/B για παρόμοιες εταιρείες ή ανταγωνιστές
| Εταιρεία | Δείκτης P/B | Διαφορά Δείκτη P/B | Χώρα |
|---|---|---|---|
| 6.251 | 48.55% |
US
|
|
| 13.2547 | 214.99% |
US
|
|
| - | - |
CH
|
|
| 6.1824 | 46.92% |
NL
|
|
| 3.2932 | -21.74% |
BE
|
